コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 11 for RA vs. ITA, and p < 0.001 for ITA vs. saphenous vein).
2 (e.g., 733 +/- 44 U/g of tissue at 6 hrs in saphenous vein).
3 duced neointimal formation in cultured human saphenous vein.
4 m aortic and coronary artery, as well as the saphenous vein.
5 panel graft constructed of recipient greater saphenous vein.
6 to those of the internal mammary artery and saphenous vein.
7 hich all others are compared--is the greater saphenous vein.
8 g-term patency of this conduit compared with saphenous vein.
9 ater than that of internal mammary artery or saphenous vein.
10 e was obtained with smooth muscle cells from saphenous vein.
11 s of normal human aorta, mammary artery, and saphenous vein.
12 reoperation over single thoracic artery with saphenous vein.
13 smooth muscle cells were cultured from human saphenous vein.
14 for the saphenous vein (p = 0.002 for RA vs. saphenous vein, 0.11 for RA vs. ITA, and p < 0.001 for I
15 ammary artery (6.2+/-0.3 pmol/mg protein) or saphenous vein (1.4+/-0.2 pmol/mg protein, both P<0.05).
16 ammary artery (3.5+/-1.3 pmol/mg protein) or saphenous vein (1.4+/-0.3 pmol/mg protein, both P<0.0001
18 89%; 95% confidence interval [CI], 86%-93%; saphenous vein, 239/269; 89%; 95% CI, 85%-93%; adjusted
21 = 65 years) in mammary artery (no change in saphenous vein), accompanied by increased alpha(1b)>alph
26 ynthase (eNOS) uncoupling were quantified in saphenous vein and internal mammary artery segments.
27 ivo release were quantified in perivascular (saphenous vein and internal mammary artery) subcutaneous
29 ent human smooth muscle cells, cultured from saphenous vein and internal mammary artery, were exposed
33 tylcholine and bradykinin were determined in saphenous veins and internal mammary arteries from 117 p
34 superoxide production was quantified in both saphenous veins and internal mammary arteries from 45 di
35 F, and total homocysteine were determined in saphenous veins and internal mammary arteries obtained d
39 3.8+/-0.8% in the internal mammary arteries, saphenous veins, and normal coronary arteries, respectiv
40 istance arteries, internal mammary arteries, saphenous veins, and small subcutaneous veins were studi
42 he angiographic patency of radial artery and saphenous vein aortocoronary bypass grafts at 5 years af
46 nous enhancement (99 HU) was observed in the saphenous vein at the ankle, with all other venous stati
47 henous veins before organ culture and in pig saphenous veins before interposition grafting into carot
48 essed TIMP-3 at the luminal surface of human saphenous veins before organ culture and in pig saphenou
50 easured by thromboelastography and prolonged saphenous-vein bleeding times, which are consistent with
51 ments from either internal mammary artery or saphenous vein, both forskolin and 8-Br-cAMP inhibited l
52 f 100 sternotomy CABG patients using IMA and saphenous veins, both treating equivalent number of targ
53 cantly augmented BH4 levels in plasma and in saphenous vein (but not internal mammary artery) but als
54 The use of aortic connectors for proximal saphenous vein bypass graft anastomoses eliminates the n
59 on in recanalization of chronically occluded saphenous vein bypass grafts in a large sample of patien
61 els and studies in patients (coronary artery saphenous vein bypass grafts, lesions of restenosis afte
64 ructive changes often occur in aortocoronary saphenous-vein bypass grafts because of atherosclerosis
65 (749 patients) were compared with those with saphenous-vein bypass grafts only (4888 patients) with r
71 nts who underwent angioplasty of an occluded saphenous vein coronary artery bypass graft between Augu
74 complications during stenting of degenerated saphenous vein coronary bypass grafts are reduced, but n
76 nstable angina, peripheral arterial disease, saphenous vein coronary bypass grafts, and diabetic reti
78 Reports of early success with cryopreserved saphenous veins (CSV) as arterial conduits led us to dev
83 ere incubated with IFN-gamma-activated human saphenous vein endothelial cells (HSVEC), but not with r
84 in bovine aortic endothelial cells and human saphenous vein endothelial cells in vitro and in adult m
85 to human erythroleukemia cells and to human saphenous vein endothelial cells was mediated by both al
87 ls of the hH1 isoform are expressed in human saphenous vein endothelium and that the presence of thes
90 s for portal interposition and cryopreserved saphenous veins for arterial interposition in liver tran
96 aft on long-term outcomes after percutaneous saphenous vein graft (SVG) intervention is currently unk
97 t of creatine kinase (CK-MB) elevation after saphenous vein graft (SVG) intervention is high, its pro
98 use of embolic protection devices (EPD) for saphenous vein graft (SVG) intervention; however, studie
100 sealing intermediate nonobstructive coronary saphenous vein graft (SVG) lesions with drug-eluting ste
102 et effect of aspirin, or both, contribute to saphenous vein graft (SVG) occlusion after coronary arte
103 pose of this study was to present radial and saphenous vein graft (SVG) occlusion results more than 5
104 assess disease progression in nonintervened saphenous vein graft (SVG) segments to determine the nat
106 63.3%) were lower for patients who underwent saphenous vein graft (SVG) stenting than for those with
107 ectiveness of gamma-irradiation ((192)Ir) in saphenous vein graft (SVG) versus native coronary artery
110 25 women) underwent stenting of 212 vessels (saphenous vein graft [53%], left anterior descending cor
111 ) or conventional treatment (n = 395) in the Saphenous Vein Graft Angioplasty Free of Emboli Randomiz
115 lower FitzGibbon A patency for arterial and saphenous vein graft conduits and less effective revascu
116 ressure balloon inflations, stents placed in saphenous vein graft conduits, and stents placed with hi
118 e use of a radial artery graft compared with saphenous vein graft did not result in greater 1-year pa
119 sis, bifurcation lesions, left main disease, saphenous vein graft disease, and acute coronary syndrom
120 ve coronary arteries, inhibit the process of saphenous vein graft disease, and improve vein graft pat
131 ative coronary artery stenoses (CAVEAT-I) or saphenous vein graft lesions (CAVEAT-II) were randomized
132 undergoing percutaneous intervention of 682 saphenous vein graft lesions were prospectively randomiz
133 ocation (78.6% in left main lesion, 69.7% in saphenous vein graft lesions, 42.4% in circumflex lesion
136 h platelet activation (deep vein thrombosis; saphenous vein graft occlusion after coronary bypass sur
138 Trials that aspirin (325 mg daily) improves saphenous vein graft patency early (7 to 10 days) and at
143 otection filter devices during uncomplicated saphenous vein graft, carotid, renal, and superficial fe
148 e center to have either the radial artery or saphenous vein grafted to a stenosed branch of the nativ
149 of patients undergoing a nonstaged multiple saphenous vein grafting (SVG) intervention with stents a
151 at the feasibility and safety of CTO PCI via saphenous vein grafts (19% of post-CABG cases) versus co
153 l conduits (85.8% versus 91.4%; P=0.003) and saphenous vein grafts (72.7% versus 80.4%; P<0.001).
154 ernal thoracic artery (LITA) supplemented by saphenous vein grafts (LITA+SVG) has been demonstrated i
156 enosis rate of 15.1%, compared with 5.9% for saphenous vein grafts (P=0.0003) and 4.8% for left inter
158 ception of patients treated with degenerated saphenous vein grafts (risk with placebo 16.3% vs. risk
160 l outcome after percutaneous intervention of saphenous vein grafts (SVG) and to identify the predicto
164 tomy prior to stent implantation in diseased saphenous vein grafts (SVGs) and thrombus-containing nat
168 Percutaneous coronary intervention (PCI) of saphenous vein grafts (SVGs) has historically been assoc
171 s related to successful stenting of diseased saphenous vein grafts (SVGs) using a novel filter-based
172 ercutaneous coronary interventions (PCIs) in saphenous vein grafts (SVGs) with thrombus have a high f
173 coronary interventions (PCIs) in degenerated saphenous vein grafts (SVGs) without distal embolic prot
174 before CABG would improve the redox state in saphenous vein grafts (SVGs), independently of low-densi
178 gnificantly better than the patency rate for saphenous vein grafts and comparable to reported patency
179 findings were similar in native arteries and saphenous vein grafts and in lesions treated with one or
180 er superior long-term survival compared with saphenous vein grafts and should be considered in patien
181 erosclerotic progression among patients with saphenous vein grafts and that aggressive lipid lowering
182 nct to percutaneous intervention of diseased saphenous vein grafts and, compared with distal protecti
185 nary stenting of stenoses in old (> 9 years) saphenous vein grafts can be successfully performed, wit
186 term studies have documented poor patency of saphenous vein grafts compared with internal thoracic ar
187 rafts are thought to be better conduits than saphenous vein grafts for coronary artery bypass graftin
190 after percutaneous intervention in diseased saphenous vein grafts is reduced by distal microcirculat
191 placebo on progression of atherosclerosis in saphenous vein grafts of patients who had had CABG surge
192 placebo on progression of atherosclerosis in saphenous vein grafts of patients who had had CABG surge
194 enever possible during treatment of diseased saphenous vein grafts produced outcomes similar to those
197 rates of drug-eluting stents, which outlive saphenous vein grafts to non-left anterior descending ve
198 Medical) was developed to rapidly anastomose saphenous vein grafts to the aorta during coronary bypas
201 l of 594 patients undergoing stenting of 639 saphenous vein grafts were prospectively randomized, usi
203 year clinical outcomes of patients receiving saphenous vein grafts with multiple (m-SVG) versus singl
204 ger vessels, in the right coronary artery or saphenous vein grafts, and for unfavorable lesion charac
205 xus and Cardiac Surgery) score, treatment of saphenous vein grafts, ostial lesions, and in-stent rest
206 anterior descending, right coronary artery, saphenous vein grafts, ostial lesions, or in-stent reste
216 , or ostial; total occlusions; bifurcations; saphenous vein grafts; and multivessel interventions) fr
218 eight years in the curve for the group with saphenous-vein grafts only than in that for the group wi
219 of 120 patients with in-stent restenosis in saphenous-vein grafts, the majority of whom had diffuse
221 up reported significantly more pain than the saphenous vein group 3 months after surgery; however, si
223 operative baseline between radial artery and saphenous vein groups after adjusting for covariates (P
224 utive patients with primary unilateral great saphenous vein (GSV) reflux undergoing endovenous treatm
225 e consequences of radial artery harvest with saphenous vein harvest in patients undergoing elective c
226 al sternal wound infection, infection at the saphenous vein harvest site, stroke, renal failure, adul
227 hundred forty-two patients with sternal and saphenous vein harvest wounds had half of each wound clo
228 factor (VWF) by immunofluorescence in great saphenous veins harvested at cardiac bypass surgery.
231 -C protein was not detected in control human saphenous veins; however, it was uniformly and strongly
232 Standard harvest and preparation of human saphenous vein (HSV) for autologous coronary and periphe
235 ion of endothelial cells cultured from human saphenous vein (HSVECs) has identified a voltage-gated N
236 function in normal and atherosclerotic human saphenous vein imply a role for the peptide in the progr
239 reduced the average time to hemostasis after saphenous vein incision, and the time to occlusion after
240 ure base, centered on the treatment of great saphenous vein incompetence cannot simply be extrapolate
241 ents, smooth muscle cells were cultured from saphenous veins, incubated with our without bacterial li
243 was to assess thrombus age in patients with saphenous vein insufficiency treated with sclerotherapy.
244 l of intimal hyperplasia, we incubated human saphenous veins, internal mammary arteries, and radial a
246 f stenotic coronary arteries with autologous saphenous vein is an established treatment for ischemic
247 number of arterial grafts into the LIMA plus saphenous veins (LIMA/SV) group (n=7435) or the MultArt
248 cation to the carotid artery (high shear) or saphenous vein (lower shear); hyperfibrinogenemia signif
251 mutation in FOXC2 showed reflux in the great saphenous vein (n=18), compared with only 1 of 12 refere
252 radial artery, internal mammary artery, and saphenous vein (n=24 patients) were examined by use of o
253 P)H oxidase activity was determined in human saphenous veins obtained from 110 patients with coronary
254 peroxide production were determined in human saphenous veins obtained from 133 patients with coronary
257 - 0.2% for the RA, and 55.0 +/- 0.2% for the saphenous vein (p = 0.002 for RA vs. saphenous vein, 0.1
258 s of culture, the I/M ratio increased in the saphenous veins (P=0.03, P=0.04 versus 0 day, respective
260 recipients: 3 of 3 organ recipients, 1 of 2 saphenous vein recipients, 1 of 3 tendon recipients, and
261 Adenovirus-mediated gene transfer to human saphenous veins resulted in functional transgene express
262 M, provokes sustained contractures in rabbit saphenous vein rings with greater efficacy than noradren
264 fibrinopeptides had no vasoactive effects on saphenous vein rings; however, fibrinogen (0-2 microM) a
265 rior descending artery, and radial artery or saphenous vein segments are used to graft the lateral an
267 nical significance was investigated by using saphenous vein segments from non-coronary heart disease
269 growth factor-stimulated migration of human saphenous vein SMCs and decrease phosphorylation of the
270 tudy, transient transfection assays in human saphenous vein smooth muscle cells (HSVSMC) and pulmonar
271 od or from adult peripheral blood, and human saphenous vein smooth muscle cells (HSVSMCs) as a source
272 n was increased in carotid atherectomies and saphenous vein specimens from diabetic versus nondiabeti
273 trial comparing treatment options for small saphenous vein (SSV) incompetence exists, and there is n
274 trial comparing treatment options for small saphenous vein (SSV) incompetence exists, and there is n
278 have significantly better patency rates than saphenous vein (SV) grafts at 5 years, but the physiolog
280 profiles of primary cultured ECs from human saphenous vein (SVEC) and coronary artery (CAEC) exposed
283 ncRNAs whose expression was altered in human saphenous vein vascular smooth muscle cells following st
285 uccessful ablation of the main trunks of the saphenous vein was less common in the foam group than in
288 Segments of internal mammary artery and saphenous vein were obtained during coronary artery bypa
289 ent, segments of internal mammary artery and saphenous vein were obtained during coronary artery bypa
290 nts, segments of internal mammary artery and saphenous vein were obtained from five patients who rece
291 Segments of internal mammary artery and saphenous vein were obtained from patients undergoing co
293 reduced the adhesion of these cells to human saphenous vein, whereas PBM adhesion in the presence of
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。